Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
- Conditions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Temple University
- Registration Number
- NCT00002508
- Locations
- 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States
Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 28
- Registration Number
- NCT00079417
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Ovarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaPrimary Peritoneal Cavity CancerStage II Ovarian Epithelial CancerStage III Ovarian Epithelial CancerFallopian Tube CancerBrenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous Cystadenocarcinoma
- Interventions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 113
- Registration Number
- NCT00079430
- Locations
- 🇯🇵
Kawasaki Medical School, Okayama-Ken, Kurashiki, Japan
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Japan Multinational Trial Organization
- Registration Number
- NCT00079287
- Locations
- 🇯🇵
Nagoya University Hospital, Aichi, Japan
🇯🇵Asahikawa Medical College, Asahikawa, Japan
🇯🇵National Hospital Organization - Ehime National Hospital, Ehime, Japan
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
- Conditions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 34
- Registration Number
- NCT00079079
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1
- Registration Number
- NCT00078988
- Locations
- 🇺🇸
Children's Hospital and Health Center - San Diego, San Diego, California, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Matrix Pharmaceutical
- Registration Number
- NCT00022217
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸Division of Head and Neck Surgery, Evanston, Illinois, United States
🇺🇸Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Cytran
- Registration Number
- NCT00017303
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸University of Kansas School of Medicine-Wichita, Wichita, Kansas, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 4
- Registration Number
- NCT00006472
- Locations
- 🇺🇸
Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸Harbor Hospital Center, Baltimore, Maryland, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00005026
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.